My Favorite Learners Podcast

New(er) to the crew: Remimazolam, Sugammadex, & Novel Opioids

15 min · 27 de abr de 2026
Portada del episodio New(er) to the crew: Remimazolam, Sugammadex, & Novel Opioids

Descripción

Today we’re diving into the future of anesthesia pharmacology with three major topics changing perioperative practice: Remimazolam, Sugammadex, and Novel Opioids. These medications were designed to improve what we care about most—faster recovery, safer profiles, more predictable pharmacokinetics, and better patient outcomes. In this episode, we break down: ✔️ Remimazolam – the ultra-short acting benzodiazepine with esterase metabolism, rapid recovery, and potential hemodynamic advantages over propofol ✔️ Sugammadex – the game-changing reversal agent for rocuronium and vecuronium, including dosing, mechanisms, risks, and board pearls ✔️ Novel Opioids – including biased agonists like oliceridine, and the ongoing search for analgesia with fewer side effects We also cover: 🎯 High-yield NBCRNA/NCE pharmacology points 🎯 Clinical pros and cons of each drug 🎯 Real-world barriers like cost, adoption, and safety concerns 🎯 How to think like an anesthesia provider—not just memorize drugs Whether you’re an SRNA, CRNA, resident, or anesthesia nerd who loves pharmacology, this episode will help you connect the science to clinical practice.

Comentarios

0

Sé la primera persona en comentar

¡Regístrate ahora y únete a la comunidad de My Favorite Learners Podcast!

Prueba gratis

Empieza 7 días de prueba

$99 / mes después de la prueba. · Cancela cuando quieras.

  • Podcasts solo en Podimo
  • 20 horas de audiolibros al mes
  • Podcast gratuitos

Todos los episodios

25 episodios

episode New(er) to the crew: Remimazolam, Sugammadex, & Novel Opioids artwork

New(er) to the crew: Remimazolam, Sugammadex, & Novel Opioids

Today we’re diving into the future of anesthesia pharmacology with three major topics changing perioperative practice: Remimazolam, Sugammadex, and Novel Opioids. These medications were designed to improve what we care about most—faster recovery, safer profiles, more predictable pharmacokinetics, and better patient outcomes. In this episode, we break down: ✔️ Remimazolam – the ultra-short acting benzodiazepine with esterase metabolism, rapid recovery, and potential hemodynamic advantages over propofol ✔️ Sugammadex – the game-changing reversal agent for rocuronium and vecuronium, including dosing, mechanisms, risks, and board pearls ✔️ Novel Opioids – including biased agonists like oliceridine, and the ongoing search for analgesia with fewer side effects We also cover: 🎯 High-yield NBCRNA/NCE pharmacology points 🎯 Clinical pros and cons of each drug 🎯 Real-world barriers like cost, adoption, and safety concerns 🎯 How to think like an anesthesia provider—not just memorize drugs Whether you’re an SRNA, CRNA, resident, or anesthesia nerd who loves pharmacology, this episode will help you connect the science to clinical practice.

27 de abr de 202615 min
episode Serotonin Syndrome, Neuroleptic Malignant Syndrome & Malignant Hyperthermia: How to Tell Them Apart artwork

Serotonin Syndrome, Neuroleptic Malignant Syndrome & Malignant Hyperthermia: How to Tell Them Apart

Three life-threatening syndromes. Similar presentations. Very different causes and treatments. In this episode, Chloe Gomez, DNP, CRNA, breaks down how to quickly differentiate Serotonin Syndrome, Neuroleptic Malignant Syndrome (NMS), and Malignant Hyperthermia (MH) - a must-know topic for anesthesia learners and board prep. We cover: ✔️ Key clinical signs and classic presentations ✔️ Triggering medications and anesthetic agents ✔️ Rigidity vs clonus vs hyperreflexia ✔️ Why ETCO₂ matters in MH ✔️ Treatment plans: cyproheptadine, dantrolene, bromocriptine, supportive care ✔️ High-yield NBCRNA/NCE test pearls ✔️ Real-world perioperative implications If you’ve ever mixed these up, this episode will help you organize them fast and remember what matters most when seconds count. 🎧 Perfect for SRNAs, CRNAs, and anyone studying advanced pharmacology.

27 de abr de 202618 min
episode Antihypertensives & Anesthesia: The Meds That Love to Mess with Your Hemodynamics with Chloe Gomez, DNP, CRNA artwork

Antihypertensives & Anesthesia: The Meds That Love to Mess with Your Hemodynamics with Chloe Gomez, DNP, CRNA

Antihypertensive medications don’t have to feel overwhelming or memorization-heavy. In this solo lecture, Chloe Gomez, DNP, CRNA breaks down antihypertensive pharmacology through physiology, mechanisms of action, and real-world anesthesia implications - exactly what SRNAs, CRNAs, and anesthesia providers need for boards and the operating room. This episode walks through the major classes of antihypertensives, focusing on how each drug lowers blood pressure rather than relying on disconnected lists. You’ll learn how antihypertensives interact with preload, afterload, heart rate, contractility, and systemic vascular resistance, and why those effects matter during induction, maintenance, and emergence from anesthesia. Key topics covered include: * Beta blockers (β₁ vs β₂ effects, perioperative continuation, blunted sympathetic response) * ACE inhibitors (ACE-Is) & ARBs: RAAS physiology, vasodilation, and refractory hypotension * Calcium channel blockers (DHP vs non-DHP): vascular vs nodal effects * Alpha agonists and antagonists * How antihypertensives alter MAP, CO, SVR, and reflex tachycardia * Why certain antihypertensives increase the risk of induction hypotension * What to hold, continue, or anticipate on the day of surgery Throughout the episode, complex pharmacology is tied directly to: * Hemodynamic management in anesthesia * Common board scenarios and NBCRNA-style reasoning * Vasopressor choice and response * Drug interactions with propofol, volatile agents, opioids, and neuraxial anesthesia This lecture emphasizes understanding over memorization, helping anesthesia learners build a framework they can use in high-stakes clinical moments - not just exam day. 🎧 Antihypertensives explained for anesthesia learners - fewer flashcards, more confidence, safer patients.

29 de dic de 202528 min